Oestrogen modulators as augmentation to antipsychotics for the treatment of post- and perimenopausal psychosis: a systematic review
Therapeutic Advances in Psychopharmacology · 2026-07 · 16
DOI: 10.1177/20451253261460148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 29.07.2026. Verfasst von Cassidy Keen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Brunel University London, School of Medicine, Kingston Lane, Uxbridge, UK. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
It is theorised that oestrogen provides neuroprotection against psychosis. Oestrogen levels drop during post- and perimenopausal periods, creating a window for the onset of psychotic symptoms. Oestrogen treatment using hormonal therapy (HT) or selective oestrogen receptor modulators (SERMs) as an adjunct to antipsychotics could provide a new treatment option for post- and perimenopausal women.
Objective
This review investigated the effectiveness of oestrogen agents as adjunctive treatment to antipsychotic medications in post- and perimenopausal women with psychosis.
Design
Systematic review. Data sources and methods: A systematic search of major databases identified trials examining oestrogen or SERMs as adjuncts to antipsychotics in women aged 40+ with psychosis. Studies were assessed for quality using the Cochrane Risk of Bias tool and the Joanna Briggs Institute (JBI) critical appraisal tools.
Results
Ten studies met inclusion criteria: one using oestrogen HT and nine using raloxifene. Reductions in total Positive and Negative Syndrome Scale (PANSS) scores support evidence for the adjunctive use of raloxifene in improving psychotic symptoms. Of the nine included clinical trials, six reported statistically significant improvements with oestrogen-modulating agents: four in total PANSS reduction, and two in positive PANSS domain only. Quality assessments identified publication bias, inconsistent data reporting and variability in study design.
Conclusion
Raloxifene shows potential as an adjunctive treatment in post- and perimenopausal psychosis, but further high-quality clinical trials are needed to inform practice and develop hormone-informed treatment protocols.
Trial registration
Not registered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Brunel University London, School of Medicine, Kingston Lane, Uxbridge, UK.
- School of Medicine, Cardiff University, Cardiff, UK.
- Cardiff University, School of Medicine, Cardiff, UK.
ORCID-Profile: Cassidy Keen, Athanasios Hassoulas
Zitieren
APA
Keen, C., Hassoulas, A., & Richardson, J. (2026). Oestrogen modulators as augmentation to antipsychotics for the treatment of post- and perimenopausal psychosis: a systematic review. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261460148
Vancouver
Keen C, Hassoulas A, Richardson J. Oestrogen modulators as augmentation to antipsychotics for the treatment of post- and perimenopausal psychosis: a systematic review. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261460148
BibTeX
@article{Keen2026,
author = {Keen, Cassidy and Hassoulas, Athanasios and Richardson, Jill},
title = {Oestrogen modulators as augmentation to antipsychotics for the treatment of post- and perimenopausal psychosis: a systematic review},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2026},
volume = {16},
doi = {10.1177/20451253261460148}
}
EUVIMED